It's a white women study ---- *A total of 247 pa

It's a white women study ----
*A total of 247 patients were included in the study...

*The mean age of the patients was 53.6±12.5 years; 58% were women, 94% were white, 42% had type 2 diabetes, and 76% had moderate or advanced fibrosis.

*In patients taking lanifibranor, a drop in hemoglobin levels was observed.

*The investigators concluded, “In this phase 2b trial of patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg once-daily dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials.”
https://fattyliver.ca/blog/f/lanifibranor-may...-with-nash

Like you, no way medical mind, but no mention of reversal, etc...

Also Lanifibranor is 1200-mg once-daily dose.
_____

Cytodyn 1st MASH news:
SMC will be conducting a twelve-week preclinical mouse study evaluating both 350 and 700 mg dose levels

Yesterday:
Leronlimab monotherapy (700 mg) demonstrated statistically significant fibrosis reversal compared to an isotype IgG4 control arm (p<0.01)

Even the dosing is a huge disparity.
Then of course LL's safety will always be any tie-breaker, if needed.

Thanks for the info --- love looking @ even possible other players!